• GSK joins NASH chase, paying $120M up front for rights to Arrowhead RNAi drug

    14 days ago - By MedCity News

    GlaxoSmithKline sees enough promise in the early clinical data of a novel NASH drug to pay its developer, Arrowhead Pharmaceuticals, $120 million up front for rights to the experimental therapy. The Arrowhead drug uses RNA interference to “silence” an enzyme associated with the progression of the fatty liver disease.
    Read more ...